Pharmaceuticals

Sterne Kessler works with branded pharmaceutical companies as well as biosimilars and generic drug companies to protect, enforce, and defend their intellectual property.

Sterne Kessler's pharmaceuticals practice integrates deep technical knowledge with legal acumen to develop robust patent portfolios, address patent validity challenges at the PTAB, and handle high-profile patent litigation, including Abbreviated New Drug Application (ANDA) and Biologics Price Competition and Innovation Act (BPCIA) matters. We work effectively with our clients to align IP with corporate strategy, and understand the advancements in life sciences that are shaping the IP landscape. Prescription & OTC Drugs Our pharmaceuticals team helps small molecule drug companies across the full range of IP—from patent prosecution and strategy, to opinions and litigation. Infectious Disease Treatments Sterne Kessler protects and defends drug and vaccine innovations developed to fight against infectious diseases. Generic Drug Development We work with generic drug developers to navigate the interface between patent law and the FDA approval process, as well as patent litigation and Abbreviated New Drug Application (ANDA) matters.

Related News & Insights

Press Release

January 29, 2020

Sterne Kessler Receives Gold Award at Innovation & IP Forum and Awards

Sterne, Kessler, Goldstein & Fox P.L.L.C.

Speaking Engagement

January 28, 2020 4:30 PM - 6:30 PM PST

Forecast for 2020: Seeing Clearly in the New Year

Reports

January 24, 2020

Federal Circuit Appeals From The PTAB: Summaries of Key 2019 Decisions

Sterne, Kessler, Goldstein & Fox